Agenus, a US-based biotechnology company headquartered in Lexington, specializes in immuno-oncology therapies targeting cancer and infectious diseases, employing 389 staff. Its pipeline includes advanced antibodies and various immunotherapy classes.
AGEN filed a patent for "t cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof" on Fri, June 23, 2023. The patent was officially published on Thu, September 12, 2024.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!